Deciphering Role of lncRNA 91H in Liver Cancer: Impact on Tumorigenesis

Document Type : Original Article


Department of Hepatobiliary Surgery, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China


Objective: This study aimed to investigate functional role of long ncRNA (lncRNA) 91H in liver cancer tumorigenesis,
focusing on its effect on cell proliferation, apoptosis, cell cycle progression, migration, invasion, epithelial-mesenchymal
transition (EMT) and in vivo tumor growth.
Materials and Methods: In this experimental study, liver cancer tissues and cell lines were analyzed for lncRNA 91H
expression using quantitative reverse transcription polymerase chain reaction (qRT-PCR). By employing si-RNA to
silence 91H, we aimed to gain a more in-depth understanding of its specific contributions and effects within these cells.
Cell proliferation was assessed through the CCK-8 assay, while apoptosis and cell cycle progression were quantified
using Annexin V-FITC staining and flow cytometry, respectively. Migration and invasion capabilities of liver cancer cells
were assessed through transwell assay. EMT was assessed by analyzing protein expression levels of EMT-associated
markers through western blotting. In vivo effect of 91H was assessed through xenograft experiments.
Results: Significantly higher levels of lncRNA 91H were observed in the liver cancer tissues and cell lines, than the
normal cells. Silencing 91H in liver cancer cells led to a notable reduction of cell proliferation by inducing apoptosis
and arresting the cell cycle. Liver cancer cells with decreased 91H expression exhibited diminished migration and
invasion abilities, suggesting a role for 91H in promoting these processes. Furthermore, 91H knockdown weakened
EMT in liver cancer cells, indicating its involvement in modulating this critical cellular transition. Furthermore, growth of
subcutaneous xenograft tumors and weight was effectively suppressed by sh-lncRNA 91H.
Conclusion: Our study strongly supports lncRNA 91H's role in liver cancer progression by enhancing proliferation, migration,
invasion, and EMT. Targeting 91H reduced in vivo tumor growth, highlighting its potential as a therapeutic liver cancer target.
These findings suggest 91H's pivotal role in liver cancer aggressiveness, opening doors for future therapeutic approaches.


Main Subjects

  1. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Bi phys Acta Rev Cancer. 2020; 1873(1): 188314.
  2. Wang G, Wang Q, Liang N, Xue H, Yang T, Chen X, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020; 11(5): 313.
  3. Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018; 67(2): 600-611.
  4. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention. J Hepatol. 2019; 70(4): 674-683.
  5. Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, et al. Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian Countries (1983-2007) and Predictions to 2030. Gastroenterology. 2018; 154(6): 1719-1728. e5.
  6. Huang J, Lok V, Ngai CH, Chu C, Patel HK, Thoguluva Chandraseka V, et al. Disease burden, risk factors, and recent trends of liver cancer: a global country-level analysis. Liver Cancer. 2021; 10(4): 330-345.
  7. Strobel O, Neoptolemos J, Jager D, Buchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019; 16(1): 11-26.
  8. Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel). 2017; 9(9): 127.
  9. von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, et al. Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget. 2017; 8(52): 89978-89987.
  10. Zhang Y, Tang L. The application of lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer Drug Discov. 2018; 13(3): 292-301.
  11. Nandwani A, Rathore S, Datta M. LncRNAs in cancer: regulatory and therapeutic implications. Cancer Lett. 2021; 501: 162-171.
  12. Wang Y, Zhu P, Luo J, Wang J, Liu Z, Wu W, et al. LncRNA HAND2- AS1 promotes liver cancer stem cell self-renewal via BMP signaling. Embo J. 2019; 38(17): e101110.
  13. Jiao Y, Li Y, Ji B, Cai H, Liu Y. Clinical value of lncRNA LUCAT1 expression in liver cancer and its potential pathways. J Gastrointestin Liver Dis. 2019; 28(4): 439-447.
  14. Hu XY, Hou PF, Li TT, Quan HY, Li ML, Lin T, et al. The roles of Wnt/beta-catenin signaling pathway related lncRNAs in cancer. Int J Biol Sci. 2018; 14(14): 2003-2011.
  15. Gao T, Liu X, He B, Nie Z, Zhu C, Zhang P, et al. Exosomal lncRNA 91H is associated with poor development in colorectal cancer by modifying HNRNPK expression. Cancer Cell Int. 2018; 18: 11.
  16. Yi T, Wang T, Shi Y, Peng X, Tang S, Zhong L, et al. Long noncoding RNA 91H overexpression contributes to the growth and metastasis of HCC by epigenetically positively regulating IGF2 expression. Liver Int. 2020; 40(2): 456-467.
  17. Liu X, She Y, Wu H, Zhong D, Zhang J. Long non-coding RNA Gas5 regulates proliferation and apoptosis in HCS-2/8 cells and growth plate chondrocytes by controlling FGF1 expression via miR-21 regulation. J Biomed Sci. 2018; 25(1): 18.
  18. Li J, Tian H, Yang J, Gong Z. Long noncoding RNAs regulate cell growth, proliferation, and apoptosis. DNA Cell Biol. 2016; 35(9): 459-470.
  19. Huo X, Han S, Wu G, Latchoumanin O, Zhou G, Hebbard L, et al. Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells. Mol Cancer. 2017; 16(1): 165.
  20. Zhao J, Fu Y, Wu J, Li J, Huang G, Qin L. The diverse mechanisms of mirnas and lncrnas in the maintenance of liver cancer stem cells. Biomed Res Int. 2018; 2018: 8686027.
  21. Deng Q, He B, Gao T, Pan Y, Sun H, Xu Y, et al. Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer. PLoS One. 2014; 9(7): e103022. 22. Vennin C, Spruyt N, Robin YM, Chassat T, Le Bourhis X, Adriaenssens
  22. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications. Cancer Lett. 2017; 385: 198-206.
  23. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020; 21(6): 341-352.
  24. Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018; 12(4): 361-373.
  25. Su J, Zhang E, Han L, Yin D, Liu Z, He X, et al. Long noncoding RNA BLACAT1 indicates a poor prognosis of colorectal cancer and affects cell proliferation by epigenetically silencing of p15. Cell Death Dis. 2017; 8(3): e2665.